How are Cochlear shares impacted by Trump's tariffs?

Will the company escape from the tariffs? Let's find out.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Ltd (ASX: COH) shares have been bouncing around on Thursday.

In morning trade, the hearing solutions company's shares were down as much as 4.5% to $256.43.

But this afternoon, they have started to recover and currently sit 0.5% lower for the day at $266.74.

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.

Image source: Getty Images

What is going on with Cochlear shares?

The company's shares were caught up in a broad market selloff this morning after US President Donald Trump made his big announcement.

From Saturday, the United States will put a minimum 10% tariff on foreign imports, including those from Australia, as part of what Trump has dubbed his "liberation day" economic plan.

This has been bad news for a number of ASX shares, such as Ansell Ltd (ASX: ANN), Breville Group Ltd (ASX: BRG), Lovisa Holdings Ltd (ASX: LOV), and Cettire Ltd (ASX: CTT). They have all fallen heavily today amid concerns over the impact that the trade tariffs could have on their respective businesses.

But what about Cochlear? How will it be impacted?

Well, the short answer is we don't know yet. Until greater detail is provided, Cochlear advised that it is unsure what the impact will be. However, there is reason to hope that the impact will not be material. This may explain why Cochlear shares have recovered from their intraday lows this afternoon.

Cochlear response

This morning, Cochlear released an announcement, explaining that it was a complex situation. It said:

There are complexities in understanding the application of the new tariff. Cochlear has long been importing its products under a chapter of the Harmonized Tariff Schedule of the United States that provides for duty-free importation on a range of products into the US, including hearing implants. We are expecting further detail in the US Customs and Border Protection Notice of Implementation, which is expected to be published in the next week. An update will be provided to the market in due course.

Judging by the way that Cochlear's shares have recovered today, it seems that some investors believe that the company will escape from the wrath of Trump's tariffs. Though, that will not be known for sure until the company releases a follow up announcement next week or the week after.

For now, the team at Citi are likely to see recent weakness as a buying opportunity. A note from last month reveals that the broker has a buy rating and $300.00 price target on the company's shares.

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in Cochlear and Lovisa. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Lovisa. The Motley Fool Australia has recommended Ansell, Cochlear, and Lovisa. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Healthcare Shares

Why are Telix shares racing 8% higher today?

Telix shares are now 11% higher for the year-to-date.

Read more »

Health professional working on his laptop.
Healthcare Shares

Why Cochlear and ResMed shares could be strong buys

Wilsons has given its verdict on these big names and it's good.

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Healthcare Shares

Which exciting ASX All Ords stock is jumping on big news?

Let's see what is getting investors excited about this stock on Wednesday.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Exciting clinical news for this ASX healthcare stock earns it a buy recommendation 

Is now the time to buy this exciting healthcare stock?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

How does Bell Potter rate these ASX healthcare stocks?

Let's see what the broker is saying about these shares.

Read more »